August 11, 2025Journal of Modern OncologyOpen Access

Novel therapies for the metastatic HER2-positive breast cancer with metastases in the central nervous system: a clinical case

View Full Paper

Ask AI

Bookmark

Authors

IRIrina M. Radyukova NRNatalia M. Rats

Discussion

Member takes

Implication

Clinical case illustrates trastuzumab deruxtecan's efficacy in patients with brain metastases, indicating potential for improved outcomes in HER2-positive breast cancer.

Key Points

Trastuzumab deruxtecan showed significant intracranial activity in metastatic HER2-positive breast cancer.
Results from the DESTINY-Breast12 phase IIIb/IV study highlighted improved outcomes for patients with brain metastases.
The introduction of new therapies offers hope for better management of complicated cases with central nervous system involvement.
Patient management now involves a personalized algorithm, emphasizing the importance of close monitoring for these complex cases.

Cite This Study

Radyukova et al. (2025) studied this question.

synapsesocial.com/papers/68c2354db210217d6476fba0 https://doi.org/10.26442/18151434.2025.2.203315

View Full Paper

Ask AI

Bookmark

Implication

Clinical case illustrates trastuzumab deruxtecan's efficacy in patients with brain metastases, indicating potential for improved outcomes in HER2-positive breast cancer.

Novel therapies for the metastatic HER2-positive breast cancer with metastases in the central nervous system: a clinical case

Discussion

Member takes

Implication

Key Points

Cite This Study

Novel therapies for the metastatic HER2-positive breast cancer with metastases in the central nervous system: a clinical case

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider